LUCD · NASDAQ
Lucid Diagnostics (LUCD) Stock Price & Fundamentals
Lucid Diagnostics (LUCD) closed at $786.37 on Oct 9, 2026, down 0.67% from the previous close of $791.66.
Share price, past year
1Y −2.07%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $786.37 |
| Sep 30, 2026 | $765.43 |
| Aug 31, 2026 | $760.00 |
| Jul 31, 2026 | $751.56 |
| Jun 30, 2026 | $739.78 |
| May 29, 2026 | $785.13 |
| Apr 30, 2026 | $772.35 |
| Mar 31, 2026 | $799.12 |
| Feb 27, 2026 | $831.32 |
| Jan 30, 2026 | $850.34 |
| Dec 31, 2025 | $826.34 |
| Nov 28, 2025 | $837.19 |
| Oct 31, 2025 | $835.93 |
Key statistics
- Market cap
- $150.01B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $5.45M
- Net income (TTM)
- −$52.26M
- Shares outstanding
- 190.8M
- Dividend yield
- —
- 52-week range
- $723.12 – $869.51
Lucid Diagnostics's market cap is $150.01B, based on a share price of $786.37 and 190.8M shares outstanding as of Jun 30, 2026.
Financials
Lucid Diagnostics reported revenue of $4.71M for fiscal 2025, up 8.28% from fiscal 2024.
Lucid Diagnostics reported a net loss of $58.01M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 5 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $4.71M | +8.3% | −$58.01M | −1,232.7% | — | −$46.68M |
| FY2024ended Dec 31, 2024 | $4.35M | +79.0% | −$45.53M | −1,047.6% | −$1.05 | −$44.44M |
| FY2023ended Dec 31, 2023 | $2.43M | +544.0% | −$52.67M | −2,169.1% | −$1.26 | — |
| FY2022ended Dec 31, 2022 | $377.00K | −24.6% | −$56.17M | −14,899.5% | −$1.55 | −$32.89M |
| FY2021ended Dec 31, 2021 | $500.00K | — | −$28.08M | −5,615.6% | −$1.51 | −$18.53M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $1.47M | −$11.69M | — |
| Q1 FY2026ended Mar 31, 2026 | $1.26M | −$13.91M | — |
| Q4 FY2025ended Dec 31, 2025 | $1.50M | −$16.27M | — |
| Q3 FY2025ended Sep 30, 2025 | $1.21M | −$10.40M | −$0.10 |
| Q2 FY2025ended Jun 30, 2025 | $1.16M | −$4.44M | −$0.08 |
| Q1 FY2025ended Mar 31, 2025 | $828.00K | −$26.91M | −$0.52 |
| Q4 FY2024ended Dec 31, 2024 | $1.20M | −$11.54M | −$0.17 |
| Q3 FY2024ended Sep 30, 2024 | $1.17M | −$12.37M | −$0.25 |
Company profile
- Name
- Lucid Diagnostics Inc.
- Ticker
- LUCD
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Surgical & Medical Instruments & Apparatus
- Headquarters
- 360 Madison Avenue, 25th Floor, New York, NY 10017
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001799011
Recent SEC filings
- Sep 22, 2026
- Aug 13, 2026
- Aug 12, 2026
- Jun 24, 2026
- May 14, 2026
- May 13, 2026
- Apr 24, 2026
- Apr 23, 2026
Frequently asked questions
What is Lucid Diagnostics's stock price?
Lucid Diagnostics (LUCD) closed at $786.37 on Oct 9, 2026, down 0.67% from the previous close of $791.66.
What is Lucid Diagnostics's market cap?
Lucid Diagnostics's market cap is $150.01B, based on a share price of $786.37 and 190.8M shares outstanding as of Jun 30, 2026.
How much revenue does Lucid Diagnostics make?
Lucid Diagnostics reported revenue of $4.71M for fiscal 2025, up 8.28% from fiscal 2024.
Does Lucid Diagnostics pay a dividend?
Lucid Diagnostics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Lucid Diagnostics Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures